Logo image
Se connecter
Retour
Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data
Article de revue   Open Access

Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data

Margitta Worm, P Demoly, Yoshitaka Okamoto, Carmen Vidal, Katia Daghildjian, Kwok Yan, Thomas Casale et Karl-Christian Bergmann
World Allergy Organization Journal, Vol.17(7)
07/2024
DOI: https://doi.org/10.1016/j.waojou.2024.100924
PMCID: PMC11259958
PMID: 39035788

Résumé

Allergic Antigens Asthma Dermatophagoides Dust mite allergy Perennial Rhinitis Sublingual immunotherapy/adverse effects
The 300IR house dust mite (HDM) sublingual immunotherapy (SLIT) tablet is approved for treatment of HDM-induced allergic rhinitis (AR). To provide a comprehensive review of the 300IR HDM-SLIT tablet safety profile based on randomized controlled trial (RCT) pooled data and post-marketing (PM) pharmacovigilance data.

Fichiers et liens (2)

url
Find in HALAfficher
url
https://doi.org/10.1016/j.waojou.2024.100924Afficher
Published (Version of record) Ouvrir

Indicateurs

1 Consultations de la notice

Détails

Logo image